Clinical Trial Update: Efficacy And Safety Of Bococizumab For Lipid Lowering In Asian Hypercholesterolemia Subjects [Phase 3]

View source ↗

Summary

Pfizer has withdrawn the Phase 3 trial evaluating bococizumab for lipid lowering in Asian subjects with primary hyperlipidemia or mixed dyslipidemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia
• Hyperlipidemia
• Mixed Dyslipidemia

Drugs mentioned

• Bococizumab (bococizumab)

Snippet

Sponsor: Pfizer | Conditions: Primary Hyperlipidemia or Mixed Dyslipidemia | Phase 3 | Status: WITHDRAWN